Dataset Open Access

Data from: Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: two open-label, randomized, safety trials

Bastiaens, Guido; Tiono, Alfred B.; Okebe, Joseph; Pett, Helmi; Coulibaly, Sam A.; Gonçalves, Bronner P.; Affara, Muna; Ouédraogo, Alphonse; Bougouma, Edith C.; Sanou, Guillaume S.; Nébié, Issa; Bradley, John; Lanke, Kjerstin H. W.; Niemi, Mikko; Sirima, Sodiomon B.; d'Alessandro, Umberto; Bousema, Teun; Drakeley, Chris; Bastiaens, Guido J. H.; Pett, Helmi E.; d'Alessandro, Umberto


MARC21 XML Export

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nmm##2200000uu#4500</leader>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Plasmodium falciparum</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">haemoglobin</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">primaquine</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">haemolysis</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">safety</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">gametocyte</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">reticulocytes</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">malaria</subfield>
  </datafield>
  <controlfield tag="005">20220529012146.0</controlfield>
  <datafield tag="500" ind1=" " ind2=" ">
    <subfield code="a">&lt;div class="o-metadata__file-usage-entry"&gt;SAFEPRIM Burkina Faso Adverse Events&lt;div class="o-metadata__file-description"&gt;Adverse events SAFEPRIM trial Burkina Faso&lt;/div&gt;&lt;div class="o-metadata__file-name"&gt;DRYAD_SAFEPRIM Burkina Faso Adverse Events.xlsx&lt;br&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="o-metadata__file-usage-entry"&gt;SAFEPRIM Gambia Adverse Events&lt;div class="o-metadata__file-description"&gt;Adverse events SAFEPRIM trial The Gambia&lt;/div&gt;&lt;div class="o-metadata__file-name"&gt;DRYAD_SAFEPRIM Gambia Adverse Events.xlsx&lt;br&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="o-metadata__file-usage-entry"&gt;DRYAD SAFEPRIM main dataset Burkina Faso&lt;div class="o-metadata__file-description"&gt;Laboratory results from clinical trial in Burkina Faso. Data include haemoglobin concentration, reticulocyte counts, full haematology and biochemistry.&lt;/div&gt;&lt;div class="o-metadata__file-name"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="o-metadata__file-usage-entry"&gt;DRYAD SAFEPRIM main dataset The Gambia&lt;div class="o-metadata__file-description"&gt;Laboratory results from clinical trial in The Gambia. Data include haemoglobin concentration, reticulocyte counts, full haematology and biochemistry.&lt;/div&gt;&lt;div class="o-metadata__file-name"&gt;&lt;/div&gt;&lt;/div&gt;&lt;p&gt;Funding provided by: National Science Foundation&lt;br&gt;Crossref Funder Registry ID: http://dx.doi.org/10.13039/100000001&lt;br&gt;Award Number: BMGF OPP1034789&lt;/p&gt;</subfield>
  </datafield>
  <controlfield tag="001">4988492</controlfield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Tiono, Alfred B.</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Medical Research Council</subfield>
    <subfield code="a">Okebe, Joseph</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Pett, Helmi</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Coulibaly, Sam A.</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Gonçalves, Bronner P.</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Medical Research Council</subfield>
    <subfield code="a">Affara, Muna</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Ouédraogo, Alphonse</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Bougouma, Edith C.</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Sanou, Guillaume S.</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Nébié, Issa</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">London School of Hygiene &amp; Tropical Medicine</subfield>
    <subfield code="a">Bradley, John</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Radboud University Nijmegen</subfield>
    <subfield code="a">Lanke, Kjerstin H. W.</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">University of Helsinki</subfield>
    <subfield code="a">Niemi, Mikko</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Sirima, Sodiomon B.</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">d'Alessandro, Umberto</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Radboud University Nijmegen</subfield>
    <subfield code="a">Bousema, Teun</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Drakeley, Chris</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Radboud University Nijmegen</subfield>
    <subfield code="a">Bastiaens, Guido J. H.</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">University of Helsinki</subfield>
    <subfield code="a">Pett, Helmi E.</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Medical Research Council</subfield>
    <subfield code="a">d'Alessandro, Umberto</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">21686</subfield>
    <subfield code="z">md5:6af382f66aeea4078dadea0717d46d7e</subfield>
    <subfield code="u">https://zenodo.org/record/4988492/files/DRYAD_SAFEPRIM Burkina Faso Adverse Events.xlsx</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">16923</subfield>
    <subfield code="z">md5:990ff03860ec1f00e5abc687521a40e9</subfield>
    <subfield code="u">https://zenodo.org/record/4988492/files/DRYAD_SAFEPRIM Gambia Adverse Events.xlsx</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">131044</subfield>
    <subfield code="z">md5:777d0ebadeaf172e44f7017c786026ee</subfield>
    <subfield code="u">https://zenodo.org/record/4988492/files/DRYAD SAFEPRIM main dataset Burkina Faso.xlsx</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">47726</subfield>
    <subfield code="z">md5:ffe860c804a2a0197ceec8004b2e6158</subfield>
    <subfield code="u">https://zenodo.org/record/4988492/files/DRYAD SAFEPRIM main dataset The Gambia.xlsx</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2018-12-18</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="p">openaire_data</subfield>
    <subfield code="p">user-dryad</subfield>
    <subfield code="o">oai:zenodo.org:4988492</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Bastiaens, Guido</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Data from: Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: two open-label, randomized, safety trials</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-dryad</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="u">https://creativecommons.org/publicdomain/zero/1.0/legalcode</subfield>
    <subfield code="a">Creative Commons Zero v1.0 Universal</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="a">cc-by</subfield>
    <subfield code="2">opendefinition.org</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">Background: Primaquine (PQ) actively clears mature Plasmodium falciparum gametocytes but in glucose-6-phosphate dehydrogenase deficient (G6PDd) individuals can cause hemolysis. We assessed the safety of low-dose PQ in combination with artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DP) in G6PDd African males with asymptomatic P. falciparum malaria.  Methods and findings: In Burkina Faso, G6PDd adult males were randomized to treatment with AL alone (n = 10) or with PQ at 0.25 (n = 20) or 0.40 mg/kg (n = 20) dosage; G6PD-normal males received AL plus 0.25 (n = 10) or 0.40 mg/kg (n = 10) PQ. In The Gambia, G6PDd adult males and boys received DP alone (n = 10) or with 0.25 mg/kg PQ (n = 20); G6PD-normal males received DP plus 0.25 (n = 10) or 0.40 mg/kg (n = 10) PQ. The primary study endpoint was change in hemoglobin concentration during the 28-day follow-up. Cytochrome P-450 isoenzyme 2D6 (CYP2D6) metabolizer status, gametocyte carriage, haptoglobin, lactate dehydrogenase levels and reticulocyte counts were also determined. In Burkina Faso, the mean maximum absolute change in hemoglobin was -2.13 g/dL (95% confidence interval [CI], -2.78, -1.49) in G6PDd individuals randomized to 0.25 PQ mg/kg and -2.29 g/dL (95% CI, -2.79, -1.79) in those receiving 0.40 PQ mg/kg. In The Gambia, the mean maximum absolute change in hemoglobin concentration was -1.83 g/dL (95% CI, -2.19, -1.47) in G6PDd individuals receiving 0.25 PQ mg/kg. After adjustment for baseline concentrations, hemoglobin reductions in G6PDd individuals in Burkina Faso were more pronounced compared to those in G6PD-normal individuals receiving the same PQ doses (P = 0.062 and P = 0.022, respectively). Hemoglobin levels normalized during follow-up. Abnormal haptoglobin and lactate dehydrogenase levels provided additional evidence of mild transient hemolysis post-PQ.  Conclusions: Single low-dose PQ in combination with AL and DP was associated with mild and transient reductions in hemoglobin. None of the study participants developed moderate or severe anemia; there were no severe adverse events. This indicates that single low-dose PQ is safe in G6PDd African males when used with artemisinin-based combination therapy.</subfield>
  </datafield>
  <datafield tag="773" ind1=" " ind2=" ">
    <subfield code="n">doi</subfield>
    <subfield code="i">isCitedBy</subfield>
    <subfield code="a">10.1371/journal.pone.0190272</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.5061/dryad.230ps</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">dataset</subfield>
  </datafield>
</record>
16
0
views
downloads
Views 16
Downloads 0
Data volume 0 Bytes
Unique views 14
Unique downloads 0

Share

Cite as